SLRN
Income statement / Annual
Last year (2024), Acelyrin, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Acelyrin, Inc.'s net income was -$248.23 M.
See Acelyrin, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$115,000.00
|
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
-$115,000.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
Research and Development Expenses |
$238.06 M
|
$355.89 M
|
$230.63 M
|
$38.23 M
|
General & Administrative Expenses |
$66.81 M
|
$66.18 M
|
$24.05 M
|
$3.56 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$66.81 M
|
$66.18 M
|
$24.05 M
|
$3.56 M
|
Other Expenses |
$11.39 M
|
$0.00
|
-$132,000.00
|
-$45,000.00
|
Operating Expenses |
$316.26 M
|
$422.06 M
|
$254.68 M
|
$41.79 M
|
Cost And Expenses |
$0.00
|
$422.06 M
|
$254.68 M
|
$41.79 M
|
Interest Income |
$31.21 M
|
$30.56 M
|
$4.17 M
|
$0.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$0.00
|
$115,000.00
|
$69,179.00
|
$41,794.00
|
EBITDA |
-$316.26 M |
-$381.53 M |
-$64.77 M |
-$41.84 M |
EBITDA Ratio |
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$68.03 M
|
$40.42 M
|
$4.41 M
|
-$45,000.00
|
Income Before Tax |
-$248.23 M
|
-$381.64 M
|
-$250.46 M
|
-$41.84 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.00
|
$0.00
|
-$4.17 M
|
-$41,794.00
|
Net Income |
-$248.23 M
|
-$381.64 M
|
-$250.46 M
|
-$41.84 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
EPS |
-2.5 |
-5.43 |
-12.25 |
-2.05 |
EPS Diluted |
-2.5 |
-5.43 |
-12.25 |
-2.05 |
Weighted Average Shares Out |
$99.30 M
|
$70.25 M
|
$20.44 M
|
$20.44 M
|
Weighted Average Shares Out Diluted |
$99.30 M
|
$70.25 M
|
$20.44 M
|
$20.44 M
|
Link |
|
|
|
|